These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38716823)

  • 1. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Nishikawa H; Tsuji K; Ishikawa T; Tajiri K; Koshiyama Y; Toyoda H; Ogawa C; Hatanaka T; Kakizaki S; Kawata K; Ohama H; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Nishimura T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Enomoto H; Kaibori M; Hiasa Y; Kudo M; ;
    Aliment Pharmacol Ther; 2024 Jul; 60(2):233-245. PubMed ID: 38716823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
    Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Piscaglia F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Pressiani T; Montes M; Vivaldi C; Soldà C; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Burgio V; Rimassa L; Scartozzi M; Cascinu S; Casadei-Gardini A
    Target Oncol; 2023 Mar; 18(2):221-233. PubMed ID: 36920648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
    Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
    Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.
    Song BG; Goh MJ; Kang W; Sinn DH; Gwak GY; Choi MS; Lee JH; Paik YH
    Gut Liver; 2024 Jul; 18(4):709-718. PubMed ID: 38932499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
    Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Asahiro M; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Masaki T; Takayama T
    Cancer Med; 2023 Feb; 12(3):2646-2657. PubMed ID: 35964253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
    J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison.
    Casadei-Gardini A; Tada T; Shimose S; Kumada T; Niizeki T; Cascinu S; Cucchetti A
    Target Oncol; 2021 Mar; 16(2):249-254. PubMed ID: 33638735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants.
    Nakabori T; Kunimasa K; Kawabata M; Higashi S; Mukai K; Kawamura T; Inoue T; Tamiya M; Nishino K; Ohkawa K
    Cancer Med; 2024 Jun; 13(12):e7430. PubMed ID: 38924675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar Efficacy Between Atezolizumab Plus Bevacizumab
    Kuwano A; Yada M; Tanaka K; Koga Y; Nagasawa S; Masumoto A; Motomura K
    In Vivo; 2024; 38(4):1854-1858. PubMed ID: 38936922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
    Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
    Hatanaka T; Naganuma A; Shibasaki M; Kohga T; Arai Y; Nagashima T; Ueno T; Namikawa M; Saito S; Hoshino T; Takizawa D; Arai H; Makita F; Kakizaki S; Harimoto N; Shirabe K; Uraoka T
    Oncology; 2021; 99(4):203-214. PubMed ID: 33279908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
    Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
    Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
    Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
    Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Hatanaka T; Tani J; Takaguchi K; Atsukawa M; Itobayashi E; Nishimura T; Tsuji K; Tajiri K; Ishikawa T; Yasuda S; Toyoda H; Fukunishi S; Ogawa C; Kakizaki S; Shimada N; Naganuma A; Kawata K; Kosaka H; Kuroda H; Matono T; Yata Y; Ochi H; Tada F; Nouso K; Morishita A; Itokawa N; Okubo T; Arai T; Tsutsui A; Nagano T; Yokohama K; Nishikawa H; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kumada T;
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2042. PubMed ID: 38577725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.
    Chon YE; Kim DY; Kim MN; Kim BK; Kim SU; Park JY; Ahn SH; Ha Y; Lee JH; Lee KS; Kang B; Kim JS; Chon HJ; Kim DY
    Clin Mol Hepatol; 2024 Jul; 30(3):345-359. PubMed ID: 38468561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma.
    Su CW; Teng W; Shen EY; Huang BS; Lin PT; Hou MM; Wu TH; Tsan DL; Hsieh CH; Wang CT; Chai PM; Lin CY; Lin SM; Lin CC
    Oncologist; 2024 Jul; 29(7):e922-e931. PubMed ID: 38530254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.